Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Lenvatinib + PD-1 Antibody for Unresectable HCC
NCT04997850Phase 2Completed
- Start
- Oct 2020
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, sintilimab, camrelizumab in hepatocellular carcinoma (HCC). Started Oct 2020; status: completed.
02
Drugs
lenvatinibsintilimabcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04997850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04997850.